NICE nods through Daiichi Sankyo's cholesterol drugs

18 March 2021

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the provision of Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ ezetimibe) on the National Health Service (NHS) in England.

Daiichi Sankyo’s (TYO: 4568) two drugs have been recommended for treating primary hypercholesterolemia or mixed dyslipidemia (heterozygous familial and non-familial) as an adjunct to diet, only if statins are contraindicated or not tolerated, and ezetimibe alone does not control low-density lipoprotein cholesterol (LDL-C) well enough.

"Availability of treatments such as these is essential in tackling cardiovascular disease"This recommendation is an important milestone for patients who will have access to two important new treatment options for lowering LDL-C, a leading risk factor for cardiovascular events, such as heart attack or stroke.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK